Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane channel-like protein 5 (TMC5)
- Target
- TMC5
- Molecular classification
- Ion channel, Transmembrane protein
01
Overview
Transmembrane channel-like protein 5 (TMC5) is a member of the TMC (transmembrane channel-like) family, predicted to function as a mechanosensitive monoatomic ion channel. It is classified as a multi-pass membrane protein expressed in various tissues. TMC5 is notably overexpressed in multiple human cancers, including prostate and gastric cancer, and is implicated in promoting tumor cell proliferation, migration, invasion, and cancer progression, primarily through regulation of the cell cycle and activation of oncogenic pathways such as PI3K/AKT, RAS/MAPK, and TSC/mTOR. Its overexpression correlates with poor prognosis in certain cancers, and TMC5 knockdown suppresses cancer cell growth and increases sensitivity to some chemotherapeutic agents (e.g., 5-fluorouracil). TMC5 is thus considered a potential therapeutic target and a biomarker for diagnosis and prognosis in oncology research[1][2][3][4].
- Other names
- Transmembrane channel-like 5TMC5UNQ8238/PRO33604FLJ13593
02
Mechanism of action
Modulation of cell cycle and proliferation through activation of signaling pathways such as PI3K/AKT, RAS/MAPK, and TSC/mTOR[2]
03
Biological functions
Cell proliferationCell cycle regulationSignal transductionCell migrationCell invasion
04
Disease associations
CancerTumor progressionProstate cancerGastric cancerVarious other cancers (correlative evidence in breast, liver, lung, ovary, etc.)
05
Safety considerations
None specifically reported in the literature; as a novel cancer-related ion channel, off-target and physiological effects outside oncology are currently under-reported or unknown
06
Interacting drugs
5-Fluorouracil (sensitivity increased upon TMC5 knockdown)[1]
2 more in the full profile.
07
Biomarkers
TMC5 expression as a potential diagnostic and prognostic biomarker in prostate, gastric, and several other cancers[1][2][3]Correlation with Gleason score and PSA in prostate cancer[1]Association with tumor microenvironment and immune cell infiltration[2]
Beyond the preview
Go deeper on Transmembrane channel-like protein 5 (TMC5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transmembrane channel-like protein 5 (TMC5).